Alzheimer's Aβ42 and Aβ40 form mixed oligomers with direct molecular interactions

Lei Gu1, Zhefeng Guo1

  • 1Department of Neurology, Brain Research Institute, Molecular Biology Institute, University of California, Los Angeles, CA, 90095, USA.

Insights

Alzheimer's disease involves amyloid-beta (Aβ) oligomers. This study shows that Aβ42 and Aβ40 peptides interact and form mixed oligomers, impacting Alzheimer's disease pathogenesis.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Molecular Biology

Background:

  • Alzheimer's disease pathogenesis involves amyloid-beta (Aβ) oligomers and fibrils.
  • Aβ42 is a major component of amyloid plaques, while Aβ40 is more abundant in the brain.
  • In vitro and in vivo studies suggest interactions between Aβ42 and Aβ40.

Purpose of the Study:

  • To investigate the interaction between Aβ42 and Aβ40 during oligomer formation.
  • To determine if Aβ42 and Aβ40 form mixed oligomers.

Main Methods:

  • Utilized electron paramagnetic resonance (EPR) spectroscopy.
  • Employed spin-labeled Aβ42 and wild-type Aβ42/Aβ40 peptides.
  • Analyzed EPR spectral changes to infer molecular interactions.

Main Results:

  • EPR spectra indicated molecular mixing when spin-labeled Aβ42 was combined with wild-type Aβ42.
  • Reduced EPR spectral amplitude when spin-labeled Aβ42 was mixed with wild-type Aβ40 suggested Aβ40 incorporation into oligomers.
  • Results demonstrate that Aβ42 and Aβ40 form mixed oligomers.

Conclusions:

  • Aβ42 and Aβ40 directly interact and form mixed oligomers.
  • Understanding these Aβ42-Aβ40 interactions is crucial for Alzheimer's disease pathogenesis research.
  • Further investigation into Aβ42-Aβ40 brain interactions is vital for therapeutic strategies.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.2K
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
11.3K
Amyloid Fibrils03:03

Amyloid Fibrils

6.1K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
596